The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Sorafenib is a kinase inhibitor drug approved for the treatment of primary kidney cancer
The global Sorafenib market was valued at US$ 915 million in 2023 and is anticipated to reach US$ 786.5 million by 2030, witnessing a CAGR of -2.2% during the forecast period 2024-2030.
Sorafenib is a targeted therapy used in the treatment of various cancers, including liver, kidney, and thyroid cancer. Factors driving market growth include the increasing incidence of these cancers, advancements in cancer treatment options, and the effectiveness of sorafenib in improving patient outcomes. The market is highly competitive, with several pharmaceutical companies manufacturing and marketing sorafenib. However, challenges such as high treatment costs, potential side effects, and the emergence of alternative therapies may hinder market growth. Nonetheless, the sorafenib market holds promising opportunities, driven by the growing global burden of cancer and the continuous research and development efforts to enhance the therapeutic potential of sorafenib.
This report aims to provide a comprehensive presentation of the global market for Sorafenib, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Sorafenib.
Report Scope
The Sorafenib market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Sorafenib market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Sorafenib manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer
Natco Pharma
Cipla
Mylan
Segment by Type
Patented Drugs
Generic Drugs
Segment by Application
Kidney Cancer
Liver Cancer
Thyroid Cancer
Other
Consumption by Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Sorafenib manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Sorafenib in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Sorafenib is a kinase inhibitor drug approved for the treatment of primary kidney cancer
The global Sorafenib market was valued at US$ 915 million in 2023 and is anticipated to reach US$ 786.5 million by 2030, witnessing a CAGR of -2.2% during the forecast period 2024-2030.
Sorafenib is a targeted therapy used in the treatment of various cancers, including liver, kidney, and thyroid cancer. Factors driving market growth include the increasing incidence of these cancers, advancements in cancer treatment options, and the effectiveness of sorafenib in improving patient outcomes. The market is highly competitive, with several pharmaceutical companies manufacturing and marketing sorafenib. However, challenges such as high treatment costs, potential side effects, and the emergence of alternative therapies may hinder market growth. Nonetheless, the sorafenib market holds promising opportunities, driven by the growing global burden of cancer and the continuous research and development efforts to enhance the therapeutic potential of sorafenib.
This report aims to provide a comprehensive presentation of the global market for Sorafenib, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Sorafenib.
Report Scope
The Sorafenib market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Sorafenib market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Sorafenib manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer
Natco Pharma
Cipla
Mylan
Segment by Type
Patented Drugs
Generic Drugs
Segment by Application
Kidney Cancer
Liver Cancer
Thyroid Cancer
Other
Consumption by Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Sorafenib manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Sorafenib in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Sorafenib Market Overview
1.1 Product Overview and Scope of Sorafenib
1.2 Sorafenib Segment by Type
1.2.1 Global Sorafenib Market Value Comparison by Type (2024-2030)
1.2.2 Patented Drugs
1.2.3 Generic Drugs
1.3 Sorafenib Segment by Application
1.3.1 Global Sorafenib Market Value by Application: (2024-2030)
1.3.2 Kidney Cancer
1.3.3 Liver Cancer
1.3.4 Thyroid Cancer
1.3.5 Other
1.4 Global Sorafenib Market Size Estimates and Forecasts
1.4.1 Global Sorafenib Revenue 2019-2030
1.4.2 Global Sorafenib Sales 2019-2030
1.4.3 Global Sorafenib Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Sorafenib Market Competition by Manufacturers
2.1 Global Sorafenib Sales Market Share by Manufacturers (2019-2024)
2.2 Global Sorafenib Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Sorafenib Average Price by Manufacturers (2019-2024)
2.4 Global Sorafenib Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Sorafenib, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Sorafenib, Product Type & Application
2.7 Sorafenib Market Competitive Situation and Trends
2.7.1 Sorafenib Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Sorafenib Players Market Share by Revenue
2.7.3 Global Sorafenib Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Sorafenib Retrospective Market Scenario by Region
3.1 Global Sorafenib Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Sorafenib Global Sorafenib Sales by Region: 2019-2030
3.2.1 Global Sorafenib Sales by Region: 2019-2024
3.2.2 Global Sorafenib Sales by Region: 2025-2030
3.3 Global Sorafenib Global Sorafenib Revenue by Region: 2019-2030
3.3.1 Global Sorafenib Revenue by Region: 2019-2024
3.3.2 Global Sorafenib Revenue by Region: 2025-2030
3.4 North America Sorafenib Market Facts & Figures by Country
3.4.1 North America Sorafenib Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Sorafenib Sales by Country (2019-2030)
3.4.3 North America Sorafenib Revenue by Country (2019-2030)
3.4.4 the United States
3.4.5 Canada
3.5 Europe Sorafenib Market Facts & Figures by Country
3.5.1 Europe Sorafenib Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Sorafenib Sales by Country (2019-2030)
3.5.3 Europe Sorafenib Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 UK
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Sorafenib Market Facts & Figures by Country
3.6.1 Asia Pacific Sorafenib Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Sorafenib Sales by Country (2019-2030)
3.6.3 Asia Pacific Sorafenib Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Sorafenib Market Facts & Figures by Country
3.7.1 Latin America Sorafenib Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Sorafenib Sales by Country (2019-2030)
3.7.3 Latin America Sorafenib Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Sorafenib Market Facts & Figures by Country
3.8.1 Middle East and Africa Sorafenib Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Sorafenib Sales by Country (2019-2030)
3.8.3 Middle East and Africa Sorafenib Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Sorafenib Sales by Type (2019-2030)
4.1.1 Global Sorafenib Sales by Type (2019-2024)
4.1.2 Global Sorafenib Sales by Type (2025-2030)
4.1.3 Global Sorafenib Sales Market Share by Type (2019-2030)
4.2 Global Sorafenib Revenue by Type (2019-2030)
4.2.1 Global Sorafenib Revenue by Type (2019-2024)
4.2.2 Global Sorafenib Revenue by Type (2025-2030)
4.2.3 Global Sorafenib Revenue Market Share by Type (2019-2030)
4.3 Global Sorafenib Price by Type (2019-2030)
5 Segment by Application
5.1 Global Sorafenib Sales by Application (2019-2030)
5.1.1 Global Sorafenib Sales by Application (2019-2024)
5.1.2 Global Sorafenib Sales by Application (2025-2030)
5.1.3 Global Sorafenib Sales Market Share by Application (2019-2030)
5.2 Global Sorafenib Revenue by Application (2019-2030)
5.2.1 Global Sorafenib Revenue by Application (2019-2024)
5.2.2 Global Sorafenib Revenue by Application (2025-2030)
5.2.3 Global Sorafenib Revenue Market Share by Application (2019-2030)
5.3 Global Sorafenib Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Bayer
6.1.1 Bayer Corporation Information
6.1.2 Bayer Description and Business Overview
6.1.3 Bayer Sorafenib Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Bayer Sorafenib Product Portfolio
6.1.5 Bayer Recent Developments/Updates
6.2 Natco Pharma
6.2.1 Natco Pharma Corporation Information
6.2.2 Natco Pharma Description and Business Overview
6.2.3 Natco Pharma Sorafenib Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Natco Pharma Sorafenib Product Portfolio
6.2.5 Natco Pharma Recent Developments/Updates
6.3 Cipla
6.3.1 Cipla Corporation Information
6.3.2 Cipla Description and Business Overview
6.3.3 Cipla Sorafenib Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Cipla Sorafenib Product Portfolio
6.3.5 Cipla Recent Developments/Updates
6.4 Mylan
6.4.1 Mylan Corporation Information
6.4.2 Mylan Description and Business Overview
6.4.3 Mylan Sorafenib Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Mylan Sorafenib Product Portfolio
6.4.5 Mylan Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Sorafenib Industry Chain Analysis
7.2 Sorafenib Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Sorafenib Production Mode & Process
7.4 Sorafenib Sales and Marketing
7.4.1 Sorafenib Sales Channels
7.4.2 Sorafenib Distributors
7.5 Sorafenib Customers
8 Sorafenib Market Dynamics
8.1 Sorafenib Industry Trends
8.2 Sorafenib Market Drivers
8.3 Sorafenib Market Challenges
8.4 Sorafenib Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
